U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H26F2N4O5
Molecular Weight 560.548
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide

SMILES

CCOC1=CN(N=C1C(=O)NC2=CC(F)=C(OC3=C4C=C(OC)C(OC)=CC4=NC=C3)C=C2)C5=C(C)C=C(F)C=C5

InChI

InChIKey=ISPBCAXOSOLFME-UHFFFAOYSA-N
InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)

HIDE SMILES / InChI
Molecular Formula C30H26F2N4O5
Molecular Weight 560.548
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

LDC1267 preferentially inhibits TAM tyrosine kinase receptors Tyro3, Axl and Mer at low nanomolarity. LDC1267 conferred therapeutic potential, efficiently enhancing anti-metastatic natural killer (NK) cells activity. In vivo the compound markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 8.0 nM [IC50]
Inhibitor
8297
 5.0 nM [IC50]
Inhibitor
8297
 29.0 nM [IC50]
Inhibitor
8297
 35.0 nM [IC50]
Inhibitor
8297
 36.0 nM [IC50]
Inhibitor
8297
 51.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
2014 Mar 27
Patents

Patents

CA2945129A1
1
WO2016183071A1
1

Sample Use Guides

In Vivo Use Guide
Mice treated intraperitoneally with LDC1267 (20 mg/kg) or by oral gavage LDC1267 (100 mg/kg).
Route of Administration: Other
In Vitro Use Guide
LDC1267 (up to 30 mM) did not affect proliferation of 84 cell lines and moderately affected proliferation of 11 cell lines (best IC50 value at ,5 mM; average IC50 value for those 11 cell lines is ,15 mM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:47:22 GMT 2023
Edited
by admin
on Fri Dec 15 16:47:22 GMT 2023
Record UNII
DK8ACB2D8P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide
Systematic Name English
1H-Pyrazole-3-carboxamide, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)-
Systematic Name English
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
Systematic Name English
LDC-1267
Common Name English
N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)-3-FLUOROPHENYL)-4-ETHOXY-1-(4-FLUORO-2-METHYLPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
Systematic Name English
LDC1267
Code English
Code System Code Type Description
PUBCHEM
56847486
Created by admin on Fri Dec 15 16:47:22 GMT 2023 , Edited by admin on Fri Dec 15 16:47:22 GMT 2023
PRIMARY
CAS
1361030-48-9
Created by admin on Fri Dec 15 16:47:22 GMT 2023 , Edited by admin on Fri Dec 15 16:47:22 GMT 2023
PRIMARY
FDA UNII
DK8ACB2D8P
Created by admin on Fri Dec 15 16:47:22 GMT 2023 , Edited by admin on Fri Dec 15 16:47:22 GMT 2023
PRIMARY
Related Record Type Details
TYROSINE-PROTEIN KINASE RECEPTOR UFO
TARGET -> INHIBITOR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966